e.l.f. Beauty Shares Plunge Following Disappointing Earnings Report

e.l.f. Beauty’s remarkable growth trajectory has hit a significant obstacle. The cosmetics company, previously a market darling, delivered a disappointing quarterly performance and substantially reduced its full-year guidance, leaving investors questioning whether this represents a temporary setback or the beginning of a prolonged downturn.

Multiple Headwinds Challenge Growth Narrative

Several factors have converged to disrupt e.l.f. Beauty’s previously unstoppable momentum. Management warnings about supply chain delays have created uncertainty among stakeholders, while increased marketing expenditures are putting pressure on profit margins. The company continues to face persistent risk from tariff duties, which are estimated at approximately 45 percent.

The critical question for market participants is whether e.l.f. Beauty can reclaim its former market standing. Future quarterly results will determine if the current sell-off represents an exaggerated market reaction or signals a fundamental shift in the company’s growth pattern.

Quarterly Results Trigger Market Sell-Off

On November 5, e.l.f. Beauty disclosed its second quarter 2026 financial results, falling substantially short of market expectations across key metrics. While revenue increased 14 percent to $343.9 million, this figure fell well below the anticipated $367.95 million. More concerning was the dramatic reduction in annual guidance: the company now projects full-year revenue of $1.55-1.57 billion, down significantly from previous expectations of $1.65 billion. Earnings projections were also slashed from $3.53 to a range of $2.80-2.85 per share.

Should investors sell immediately? Or is it worth buying elf Beauty?

Investors responded decisively to the disappointing news. The stock plummeted 20 percent in a single session and has now declined over 40 percent since pre-earnings expectations began deteriorating. This downward movement pushed shares to their 52-week low—a striking reversal for a company that had previously reported 27 consecutive quarters of growth.

Analyst Community Downgrades Price Targets

The negative sentiment quickly spread throughout the analyst community, with nearly all major firms substantially reducing their price targets:

• UBS lowered its target from $150 to $105 while maintaining a “Neutral” rating
• TD Cowen adjusted its target downward from $145 to $110
• Raymond James reduced its target from $165 to $135
• Jefferies decreased its target from $150 to $120

Even Piper Sandler, which maintained its “Neutral” rating, now sees the stock reaching only $100 per share. The average analyst price target has consequently dropped from approximately $153 to $122, clearly reflecting diminished growth expectations across the financial analysis sector.